Research information only — not medical advice. Full disclaimer
Peptide Library

Peptide profile

Skin & hair Immune support Metabolic Clinical evidence

Melanotan I

Clinical-grade melanocyte activator for photoprotection · also known as MT-1, Afamelanotide, CUV1647, NDP-α-MSH

Compare Melanotan I with other peptides →

Summary

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that potently stimulates melanogenesis, increasing skin pigmentation without requiring UV exposure. It was developed primarily to protect individuals with photosensitive conditions such as erythropoietic protoporphyria (EPP) from painful phototoxic reactions. Beyond tanning, it has demonstrated anti-inflammatory, photoprotective, and potentially immunomodulatory effects in clinical and preclinical studies.

Typical dose
500 mcg–1 mg/day (research use); clinical EPP implant delivers 16 mg/60 days
Half-life
~1–2 hours (subcutaneous injection)
Route
Subcutaneous, Intramuscular
Cycle length
4–8 weeks (research context); implant duration ~60 days (clinical)

Mechanism

How it works

Melanotan I binds to and activates melanocortin receptors, principally MC1R on melanocytes, triggering the cAMP–protein kinase A signaling cascade that upregulates tyrosinase activity and eumelanin synthesis. Increased eumelanin in keratinocytes provides photoprotective pigmentation by absorbing and scattering UV radiation. MC1R activation also suppresses NF-κB-mediated inflammatory cytokine production, contributing to the compound's anti-inflammatory properties.

Reported in research

Benefits

  • Significantly increases skin pigmentation (eumelanin) independent of UV radiation exposure
  • Reduces phototoxic pain episodes in erythropoietic protoporphyria (EPP) — FDA/EMA-approved indication for afamelanotide
  • Provides photoprotection by increasing UV-absorbing melanin in the skin
  • Demonstrates anti-inflammatory effects via MC1R-mediated suppression of pro-inflammatory cytokines

Context, not a prescription

Dosing

Typical range
500 mcg–1 mg/day (research use); clinical EPP implant delivers 16 mg/60 days (Subcutaneous, Intramuscular)
Cycle length
4–8 weeks (research context); implant duration ~60 days (clinical)
Half-life
~1–2 hours (subcutaneous injection)

Safety

Side effects & contraindications

Possible side effects

  • Nausea (especially at higher doses or rapid titration)
  • Flushing and facial redness
  • Spontaneous erections (less common than with Melanotan II due to lower MC4R affinity)
  • Fatigue and lethargy
  • Darkening of existing moles and nevi — requires dermatological monitoring
  • Headache
  • Injection site reactions (bruising, redness)

Contraindications

  • Personal or family history of melanoma or dysplastic nevus syndrome — increased pigmentation may obscure lesion monitoring
  • Active autoimmune skin disorders where altered pigmentation could be harmful
  • Pregnancy and breastfeeding — insufficient safety data
  • Hypersensitivity to α-MSH analogues or any peptide excipients

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Gradual, even darkening of skin tone; existing moles and freckles may also darken. Some users report mild nausea early on, which usually subsides. Skin becomes noticeably more resistant to sunburn.

How it works

Think of Melanotan I as a key that fits specifically into your skin cells' 'tanning switch' (MC1R). When you insert the key and turn it, the cells start producing dark pigment — like turning up the volume on a speaker that was already on but set low.

After injection, Melanotan I travels through the bloodstream to melanocytes in the skin. These cells respond by ramping up melanin production over days to weeks. The pigment then migrates into surrounding skin cells (keratinocytes), creating a natural-looking tan that lasts beyond the dosing period.

What to expect

Initial flushing or redness may occur within 30–60 minutes of the first injection. Visible skin darkening typically begins within 5–10 days of regular dosing, with full effect seen over 3–6 weeks.

  • Week 1: Initial nausea and flushing may occur with first few injections. Minimal visible tan change, but melanocytes are beginning to activate.
  • Weeks 2–4: Visible skin darkening becomes apparent, especially on sun-exposed areas. Nausea typically subsides. Photoprotective effect begins to develop.
  • Weeks 4–8: Pigmentation reaches a plateau. Skin tone is noticeably darker and more even. Benefits persist for weeks after stopping due to accumulated melanin.

Good to know

  • Start at the lowest effective dose (e.g., 250–500 mcg) and increase slowly to minimize nausea
  • Get a full skin check from a dermatologist before and during use, especially to monitor existing moles

Staying safe

  • Nausea within the first hour after injection, especially early in the cycle
  • Flushing and warmth in the face shortly after dosing
  • Mild headache
  • Darkening of moles (requires monitoring)

Avoid if you have:

  • Anyone with a personal or family history of melanoma or atypical moles
  • Pregnant or breastfeeding women
  • People with autoimmune skin conditions

Overview

Progressive eumelanin deposition in the epidermis with corresponding rise in ITA° (Individual Typology Angle) scores. Histologically: increased melanocyte dendricity, upregulated tyrosinase immunoreactivity, and denser melanosome transfer to keratinocytes. MED (minimal erythema dose) increases, reflecting genuine photoprotection. Anti-inflammatory markers (serum IL-6, skin TNF-α) may be reduced with sustained dosing.

How it works

If melanocyte signaling were an orchestra, endogenous α-MSH would be the conductor occasionally tapping the baton. Melanotan I is a conductor with a louder voice, more precise baton technique, and resistance to being pulled off stage — delivering a sustained, targeted performance from the first-chair melanin instruments (MC1R) without inappropriately cuing the brass section (MC4R) that controls appetite and sexual function.

Following subcutaneous or intramuscular injection, Melanotan I achieves peak plasma concentrations within 30–60 minutes (Tmax ~0.5–1 h). Its plasma half-life is approximately 1–2 hours, but the downstream biological effect on MITF-driven transcription and melanin synthesis persists far beyond plasma clearance — resulting in a prolonged pigmentary response (days to weeks). In the clinical EPP application, a subcutaneous biodegradable poly(lactic-co-glycolic acid) implant releasing ~0.27 mg/day maintains trough plasma concentrations that continuously saturate MC1R, preventing the painful phototoxic crises triggered by protoporphyrin IX photoactivation.

Onset & timeline

Vasoactive effects (flushing, mild erections) may appear within 30–60 minutes of the first injection. Measurable increases in skin colorimetry (melanin index) are detectable within 7–10 days. Full phototype shift typically requires 3–6 weeks of consistent dosing. In EPP clinical trials, significant reduction in phototoxic episodes was reported within 2 weeks of implant placement.

  • Days 1–3: Initial pharmacodynamic responses: transient cAMP spike in melanocytes; flushing and possible mild nausea as peripheral melanocortin receptors are engaged. Plasma t½ ~1–2 h; no visible pigment change yet.
  • Weeks 1–2: MITF and tyrosinase mRNA upregulation measurable in skin biopsies. Melanin index (Mexameter) begins to rise. Nausea typically resolves as receptor desensitization partially attenuates early autonomic side effects.
  • Weeks 2–8: Progressive and even eumelanin accumulation; phototype shift of 1–2 Fitzpatrick grades in some users. Photoprotective effect is functional by week 3–4. Pigmentation may plateau and sustains for 4–8 weeks post-cessation due to melanin turnover kinetics.

Getting the most from it

  • Conduct baseline and periodic (every 4–8 weeks) full-body dermatoscopic skin examinations to monitor for new or changing melanocytic lesions
  • Use a conservative dose-escalation protocol starting at 250 mcg to minimize nausea and vasomotor side effects before titrating to 500–1000 mcg
  • Avoid concomitant use with photosensitizing agents (e.g., psoralens, certain NSAIDs, tetracyclines) to prevent exaggerated UV responses
  • Reconstitute with bacteriostatic water only; use sterile technique and rotate injection sites to minimize infection and tissue irritation risk

Common side effects

  • Nausea (dose-dependent, mediated by peripheral MC3R/MC4R activation; typically transient within first 1–2 weeks)
  • Transient facial flushing and erythema (vasodilatory effect via nitric oxide pathway)
  • Hyperpigmentation of nevi — documented in clinical trials; requires dermatoscopic monitoring
  • Headache (likely related to transient vasodilation)

Mechanism of action

Melanotan I is [Nle4, D-Phe7]-α-MSH, a linear 13-amino acid synthetic analogue of endogenous α-MSH with substitutions conferring enhanced receptor affinity and proteolytic resistance. It activates MC1R with high selectivity (Ki ~0.2 nM at MC1R vs. significantly weaker binding at MC3R/MC4R/MC5R), stimulating Gs protein-coupled adenylyl cyclase, elevating intracellular cAMP, and activating PKA. PKA phosphorylates CREB, which transcriptionally upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. This drives tyrosinase, TRP-1, and TRP-2 expression, shifting melanin production toward photoprotective eumelanin over pheomelanin. Additionally, MC1R signaling suppresses NF-κB nuclear translocation and reduces IL-6, TNF-α, and IL-1β output from activated keratinocytes and immune cells, providing a mechanistic basis for its photoprotective anti-inflammatory effects.

Following subcutaneous or intramuscular injection, Melanotan I achieves peak plasma concentrations within 30–60 minutes (Tmax ~0.5–1 h). Its plasma half-life is approximately 1–2 hours, but the downstream biological effect on MITF-driven transcription and melanin synthesis persists far beyond plasma clearance — resulting in a prolonged pigmentary response (days to weeks). In the clinical EPP application, a subcutaneous biodegradable poly(lactic-co-glycolic acid) implant releasing ~0.27 mg/day maintains trough plasma concentrations that continuously saturate MC1R, preventing the painful phototoxic crises triggered by protoporphyrin IX photoactivation.

Pharmacodynamics

Vasoactive effects (flushing, mild erections) may appear within 30–60 minutes of the first injection. Measurable increases in skin colorimetry (melanin index) are detectable within 7–10 days. Full phototype shift typically requires 3–6 weeks of consistent dosing. In EPP clinical trials, significant reduction in phototoxic episodes was reported within 2 weeks of implant placement.

Progressive eumelanin deposition in the epidermis with corresponding rise in ITA° (Individual Typology Angle) scores. Histologically: increased melanocyte dendricity, upregulated tyrosinase immunoreactivity, and denser melanosome transfer to keratinocytes. MED (minimal erythema dose) increases, reflecting genuine photoprotection. Anti-inflammatory markers (serum IL-6, skin TNF-α) may be reduced with sustained dosing.

Timeline

  • Days 1–3: Initial pharmacodynamic responses: transient cAMP spike in melanocytes; flushing and possible mild nausea as peripheral melanocortin receptors are engaged. Plasma t½ ~1–2 h; no visible pigment change yet.
  • Weeks 1–2: MITF and tyrosinase mRNA upregulation measurable in skin biopsies. Melanin index (Mexameter) begins to rise. Nausea typically resolves as receptor desensitization partially attenuates early autonomic side effects.
  • Weeks 2–8: Progressive and even eumelanin accumulation; phototype shift of 1–2 Fitzpatrick grades in some users. Photoprotective effect is functional by week 3–4. Pigmentation may plateau and sustains for 4–8 weeks post-cessation due to melanin turnover kinetics.

Comparisons

  • Melanotan I (MT-1) — effectiveness Very High, safety Good, cost $$, Medium to use
  • Melanotan II (MT-2) — effectiveness Very High, safety Moderate, cost $$, Medium to use
  • Bremelanotide (PT-141) — effectiveness High, safety Good, cost $$$, Medium to use

Adverse effects

Common:

  • Nausea (dose-dependent, mediated by peripheral MC3R/MC4R activation; typically transient within first 1–2 weeks)
  • Transient facial flushing and erythema (vasodilatory effect via nitric oxide pathway)
  • Hyperpigmentation of nevi — documented in clinical trials; requires dermatoscopic monitoring
  • Headache (likely related to transient vasodilation)

Rare:

  • Spontaneous erections or increased libido (rare vs. MT-II, due to low MC4R affinity; reported in <5% of subjects in trials)
  • New or rapidly changing melanocytic lesions (rare but clinically significant — mandates dermatological evaluation)
  • Injection site granuloma (with repeated injections at the same site)

Contraindications & risk mitigation

Contraindicated in:

  • Personal or family history of cutaneous malignant melanoma, dysplastic nevus syndrome, or multiple atypical nevi — MC1R activation may accelerate melanocyte proliferation in susceptible individuals
  • Patients on immunosuppressive therapy — altered immune surveillance may complicate monitoring of pigmented lesions
  • Renal or hepatic impairment — peptide clearance data are limited; dosing adjustments may be necessary
  • Pregnancy and lactation — no controlled human safety data; animal reproductive toxicology is limited
  • Conduct baseline and periodic (every 4–8 weeks) full-body dermatoscopic skin examinations to monitor for new or changing melanocytic lesions
  • Use a conservative dose-escalation protocol starting at 250 mcg to minimize nausea and vasomotor side effects before titrating to 500–1000 mcg
  • Avoid concomitant use with photosensitizing agents (e.g., psoralens, certain NSAIDs, tetracyclines) to prevent exaggerated UV responses
  • Reconstitute with bacteriostatic water only; use sterile technique and rotate injection sites to minimize infection and tissue irritation risk

Qué hace

Gradual, even darkening of skin tone; existing moles and freckles may also darken. Some users report mild nausea early on, which usually subsides. Skin becomes noticeably more resistant to sunburn.

Cómo funciona

Think of Melanotan I as a key that fits specifically into your skin cells' 'tanning switch' (MC1R). When you insert the key and turn it, the cells start producing dark pigment — like turning up the volume on a speaker that was already on but set low.

After injection, Melanotan I travels through the bloodstream to melanocytes in the skin. These cells respond by ramping up melanin production over days to weeks. The pigment then migrates into surrounding skin cells (keratinocytes), creating a natural-looking tan that lasts beyond the dosing period.

Qué esperar

Initial flushing or redness may occur within 30–60 minutes of the first injection. Visible skin darkening typically begins within 5–10 days of regular dosing, with full effect seen over 3–6 weeks.

  • Week 1: Initial nausea and flushing may occur with first few injections. Minimal visible tan change, but melanocytes are beginning to activate.
  • Weeks 2–4: Visible skin darkening becomes apparent, especially on sun-exposed areas. Nausea typically subsides. Photoprotective effect begins to develop.
  • Weeks 4–8: Pigmentation reaches a plateau. Skin tone is noticeably darker and more even. Benefits persist for weeks after stopping due to accumulated melanin.

Bueno saber

  • Start at the lowest effective dose (e.g., 250–500 mcg) and increase slowly to minimize nausea
  • Get a full skin check from a dermatologist before and during use, especially to monitor existing moles

Manteniéndose seguro

  • Nausea within the first hour after injection, especially early in the cycle
  • Flushing and warmth in the face shortly after dosing
  • Mild headache
  • Darkening of moles (requires monitoring)

Evitar si tienes:

  • Anyone with a personal or family history of melanoma or atypical moles
  • Pregnant or breastfeeding women
  • People with autoimmune skin conditions

Descripción general

Progressive eumelanin deposition in the epidermis with corresponding rise in ITA° (Individual Typology Angle) scores. Histologically: increased melanocyte dendricity, upregulated tyrosinase immunoreactivity, and denser melanosome transfer to keratinocytes. MED (minimal erythema dose) increases, reflecting genuine photoprotection. Anti-inflammatory markers (serum IL-6, skin TNF-α) may be reduced with sustained dosing.

Cómo funciona

If melanocyte signaling were an orchestra, endogenous α-MSH would be the conductor occasionally tapping the baton. Melanotan I is a conductor with a louder voice, more precise baton technique, and resistance to being pulled off stage — delivering a sustained, targeted performance from the first-chair melanin instruments (MC1R) without inappropriately cuing the brass section (MC4R) that controls appetite and sexual function.

Following subcutaneous or intramuscular injection, Melanotan I achieves peak plasma concentrations within 30–60 minutes (Tmax ~0.5–1 h). Its plasma half-life is approximately 1–2 hours, but the downstream biological effect on MITF-driven transcription and melanin synthesis persists far beyond plasma clearance — resulting in a prolonged pigmentary response (days to weeks). In the clinical EPP application, a subcutaneous biodegradable poly(lactic-co-glycolic acid) implant releasing ~0.27 mg/day maintains trough plasma concentrations that continuously saturate MC1R, preventing the painful phototoxic crises triggered by protoporphyrin IX photoactivation.

Inicio y cronología

Vasoactive effects (flushing, mild erections) may appear within 30–60 minutes of the first injection. Measurable increases in skin colorimetry (melanin index) are detectable within 7–10 days. Full phototype shift typically requires 3–6 weeks of consistent dosing. In EPP clinical trials, significant reduction in phototoxic episodes was reported within 2 weeks of implant placement.

  • Days 1–3: Initial pharmacodynamic responses: transient cAMP spike in melanocytes; flushing and possible mild nausea as peripheral melanocortin receptors are engaged. Plasma t½ ~1–2 h; no visible pigment change yet.
  • Weeks 1–2: MITF and tyrosinase mRNA upregulation measurable in skin biopsies. Melanin index (Mexameter) begins to rise. Nausea typically resolves as receptor desensitization partially attenuates early autonomic side effects.
  • Weeks 2–8: Progressive and even eumelanin accumulation; phototype shift of 1–2 Fitzpatrick grades in some users. Photoprotective effect is functional by week 3–4. Pigmentation may plateau and sustains for 4–8 weeks post-cessation due to melanin turnover kinetics.

Cómo aprovecharlo al máximo

  • Conduct baseline and periodic (every 4–8 weeks) full-body dermatoscopic skin examinations to monitor for new or changing melanocytic lesions
  • Use a conservative dose-escalation protocol starting at 250 mcg to minimize nausea and vasomotor side effects before titrating to 500–1000 mcg
  • Avoid concomitant use with photosensitizing agents (e.g., psoralens, certain NSAIDs, tetracyclines) to prevent exaggerated UV responses
  • Reconstitute with bacteriostatic water only; use sterile technique and rotate injection sites to minimize infection and tissue irritation risk

Efectos secundarios comunes

  • Nausea (dose-dependent, mediated by peripheral MC3R/MC4R activation; typically transient within first 1–2 weeks)
  • Transient facial flushing and erythema (vasodilatory effect via nitric oxide pathway)
  • Hyperpigmentation of nevi — documented in clinical trials; requires dermatoscopic monitoring
  • Headache (likely related to transient vasodilation)

Mecanismo de acción

Melanotan I is [Nle4, D-Phe7]-α-MSH, a linear 13-amino acid synthetic analogue of endogenous α-MSH with substitutions conferring enhanced receptor affinity and proteolytic resistance. It activates MC1R with high selectivity (Ki ~0.2 nM at MC1R vs. significantly weaker binding at MC3R/MC4R/MC5R), stimulating Gs protein-coupled adenylyl cyclase, elevating intracellular cAMP, and activating PKA. PKA phosphorylates CREB, which transcriptionally upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. This drives tyrosinase, TRP-1, and TRP-2 expression, shifting melanin production toward photoprotective eumelanin over pheomelanin. Additionally, MC1R signaling suppresses NF-κB nuclear translocation and reduces IL-6, TNF-α, and IL-1β output from activated keratinocytes and immune cells, providing a mechanistic basis for its photoprotective anti-inflammatory effects.

Following subcutaneous or intramuscular injection, Melanotan I achieves peak plasma concentrations within 30–60 minutes (Tmax ~0.5–1 h). Its plasma half-life is approximately 1–2 hours, but the downstream biological effect on MITF-driven transcription and melanin synthesis persists far beyond plasma clearance — resulting in a prolonged pigmentary response (days to weeks). In the clinical EPP application, a subcutaneous biodegradable poly(lactic-co-glycolic acid) implant releasing ~0.27 mg/day maintains trough plasma concentrations that continuously saturate MC1R, preventing the painful phototoxic crises triggered by protoporphyrin IX photoactivation.

Farmacodinamia

Vasoactive effects (flushing, mild erections) may appear within 30–60 minutes of the first injection. Measurable increases in skin colorimetry (melanin index) are detectable within 7–10 days. Full phototype shift typically requires 3–6 weeks of consistent dosing. In EPP clinical trials, significant reduction in phototoxic episodes was reported within 2 weeks of implant placement.

Progressive eumelanin deposition in the epidermis with corresponding rise in ITA° (Individual Typology Angle) scores. Histologically: increased melanocyte dendricity, upregulated tyrosinase immunoreactivity, and denser melanosome transfer to keratinocytes. MED (minimal erythema dose) increases, reflecting genuine photoprotection. Anti-inflammatory markers (serum IL-6, skin TNF-α) may be reduced with sustained dosing.

Cronología

  • Days 1–3: Initial pharmacodynamic responses: transient cAMP spike in melanocytes; flushing and possible mild nausea as peripheral melanocortin receptors are engaged. Plasma t½ ~1–2 h; no visible pigment change yet.
  • Weeks 1–2: MITF and tyrosinase mRNA upregulation measurable in skin biopsies. Melanin index (Mexameter) begins to rise. Nausea typically resolves as receptor desensitization partially attenuates early autonomic side effects.
  • Weeks 2–8: Progressive and even eumelanin accumulation; phototype shift of 1–2 Fitzpatrick grades in some users. Photoprotective effect is functional by week 3–4. Pigmentation may plateau and sustains for 4–8 weeks post-cessation due to melanin turnover kinetics.

Comparaciones

  • Melanotan I (MT-1) — efectividad Very High, seguridad Good, costo $$, Medium de usar
  • Melanotan II (MT-2) — efectividad Very High, seguridad Moderate, costo $$, Medium de usar
  • Bremelanotide (PT-141) — efectividad High, seguridad Good, costo $$$, Medium de usar

Efectos adversos

Comunes:

  • Nausea (dose-dependent, mediated by peripheral MC3R/MC4R activation; typically transient within first 1–2 weeks)
  • Transient facial flushing and erythema (vasodilatory effect via nitric oxide pathway)
  • Hyperpigmentation of nevi — documented in clinical trials; requires dermatoscopic monitoring
  • Headache (likely related to transient vasodilation)

Raros:

  • Spontaneous erections or increased libido (rare vs. MT-II, due to low MC4R affinity; reported in <5% of subjects in trials)
  • New or rapidly changing melanocytic lesions (rare but clinically significant — mandates dermatological evaluation)
  • Injection site granuloma (with repeated injections at the same site)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

  • Personal or family history of cutaneous malignant melanoma, dysplastic nevus syndrome, or multiple atypical nevi — MC1R activation may accelerate melanocyte proliferation in susceptible individuals
  • Patients on immunosuppressive therapy — altered immune surveillance may complicate monitoring of pigmented lesions
  • Renal or hepatic impairment — peptide clearance data are limited; dosing adjustments may be necessary
  • Pregnancy and lactation — no controlled human safety data; animal reproductive toxicology is limited
  • Conduct baseline and periodic (every 4–8 weeks) full-body dermatoscopic skin examinations to monitor for new or changing melanocytic lesions
  • Use a conservative dose-escalation protocol starting at 250 mcg to minimize nausea and vasomotor side effects before titrating to 500–1000 mcg
  • Avoid concomitant use with photosensitizing agents (e.g., psoralens, certain NSAIDs, tetracyclines) to prevent exaggerated UV responses
  • Reconstitute with bacteriostatic water only; use sterile technique and rotate injection sites to minimize infection and tissue irritation risk

Reference data

Specifications

Molecular formula
C78H111N21O19
Molecular weight
1646.85 g/mol
Half-life
~1–2 hours (subcutaneous injection)
Route
Subcutaneous, Intramuscular
Cycle length
4–8 weeks (research context); implant duration ~60 days (clinical)
Storage
Lyophilized powder: store at 2–8°C (refrigerated), protect from light and moisture. Reconstituted solution: store at 2–8°C, use within 5–7 days. Avoid freeze-thaw cycles of reconstituted peptide.
Legal status
Approved as Scenesse (afamelanotide 16 mg implant) by EMA (2014) and FDA (2019) for EPP. Research-grade injectable MT-1 is unregulated for personal use in most jurisdictions but is not approved for cosmetic tanning. Regulatory status varies by country.

FAQ

Common questions

How does Melanotan I differ pharmacologically from endogenous α-MSH?

Endogenous α-MSH is a 13-amino acid peptide cleaved from POMC with a short plasma half-life (~10–20 minutes) due to rapid enzymatic degradation. Melanotan I incorporates a [Nle4, D-Phe7] substitution: norleucine replaces methionine at position 4 (improving oxidative stability) and D-phenylalanine replaces L-phenylalanine at position 7 (conferring resistance to proteolytic cleavage and increasing MC1R binding affinity 10–100-fold). This results in a prolonged biological effect relative to its plasma half-life.

What is the evidence base for its use in EPP?

A pivotal Phase III RCT (Langendonk et al., NEJM, 2015) demonstrated that the 16 mg afamelanotide implant significantly increased the time patients with EPP could spend in sunlight without pain (median 69.4 vs. 40.8 minutes, p<0.001) compared to placebo. This trial supported EMA approval in 2014 and FDA approval in 2019 under the brand name Scenesse (CLINUVEL Pharmaceuticals).

Is there a risk of melanoma with prolonged use?

Theoretical concern exists because MC1R activation drives melanocyte proliferation. Post-marketing surveillance and clinical trial data for afamelanotide have not demonstrated an increased melanoma incidence, but monitoring protocols including regular dermatoscopy are mandatory in clinical use. Research-grade use outside controlled settings lacks this structured oversight — this is a significant safety gap.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for Melanotan I is rated as Clinical evidence. Human clinical evidence supports the reported effects.

  1. 1. Afamelanotide for Erythropoietic Protoporphyria (Phase III RCT) (2015) — New England Journal of Medicine — Langendonk JG et al., NEJM 373:48–59
  2. 2. MC1R biology and the pigmentary response to alpha-MSH (2006) — Pigment Cell Research — Garcia-Borron JC et al.
  3. 3. FDA Approval of Scenesse (afamelanotide) NDA 210797 (2019) — FDA.gov Center for Drug Evaluation and Research
  4. 4. Anti-inflammatory effects of alpha-MSH analogues via MC1R (2010) — Journal of Leukocyte Biology — Luger TA et al.

Explore

Often discussed alongside

Melanotan II · skin GHK-Cu · skin Thymosin Alpha-1 · immune BPC-157 · healing